Epilepsy is one of the most common and disabling chronic neurological disorders.
Antiseizure medications (ASMs), previously referred to as anticonvulsant or antiepileptic …

Drug resistance is estimated to affect about a third of individuals with epilepsy, but its
prevalence differs in relation to the epilepsy syndrome, the cause of epilepsy, and other …

Rationally designed multi-target drugs (also termed multimodal drugs, network therapeutics,
or designed multiple ligands) have emerged as an attractive drug discovery paradigm in the …

Free radicals are generated in the brain, as well as in other organs, and their production is
proportional to the brain activity. Due to its low antioxidant capacity, the brain is particularly …

In the last 30 years, over 20 new anti-seizure medicines (ASMs) have been introduced into
the market for the treatment of epilepsy using well-established preclinical seizure and …

Drug resistance is a major challenge in the treatment of epilepsy. Drug-resistant epilepsy
(DRE) accounts for 30% of all cases of epilepsy and is a matter of great concern because of …

As one of the most prevalent and disabling brain disorders, epilepsy is characterized by
spontaneous seizures that result from aberrant, excessive hyperactivity of a group of highly …

Seizures are a common presenting symptom during viral infections of the central nervous
system (CNS) and can occur during the initial phase of infection (“early” or acute …

Objective Unidentified mechanisms largely restrict the viability of effective therapies in
pharmacoresistant epilepsy. Our previous study revealed that hyperactivity of the subiculum …

Epilepsies are common chronic neurological diseases characterized by recurrent
unprovoked seizures of central origin. The mainstay of treatment involves symptomatic …